<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02242006</url>
  </required_header>
  <id_info>
    <org_study_id>20140429</org_study_id>
    <nct_id>NCT02242006</nct_id>
  </id_info>
  <brief_title>Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)</brief_title>
  <official_title>Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <brief_summary>
    <textblock>
      Severe acute kidney injury (AKI) is a common complication of critical illness affecting&#xD;
      almost half of all patients with septic shock. Extracorporeal renal replacement therapy is a&#xD;
      cornerstone in the management of AKI in these patients. Options for renal replacement therapy&#xD;
      include continuous renal replacement (CRRT) therapy, intermittent dialysis (IHD) or a hybrid&#xD;
      form of the two called sustained low efficiency dialysis (SLED). Globally there is a push to&#xD;
      switch from traditional CRRT to SLED. Although there are resource and financial comparative&#xD;
      benefits to SLED there is almost no literature describing how to dose antimicrobials (or&#xD;
      other drugs for that matter). It appears that drug clearance on SLED may be more efficient&#xD;
      than CRRT but not as efficient as IHD making extrapolation from these bodies of literature&#xD;
      inappropriate for SLED. The investigators are proposing to conduct the population&#xD;
      pharmacokinetic studies for the three most commonly used antimicrobials in critically ill&#xD;
      patients receiving SLED therapy (piperacillin-tazobactam, meropenem and vancomycin).&#xD;
      Population pharmacokinetic modeling of these drugs will provide estimates and sources of&#xD;
      variability around pharmacokinetic parameters that will subsequently be used for Monte Carlo&#xD;
      simulation to determine the most appropriate dosing regimens to achieve therapeutic targets&#xD;
      while minimizing the risk of toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>drug clearance</measure>
    <time_frame>During the first run of SLED after study inclusion</time_frame>
    <description>Serial serum samples will be obtained after drug administration and during SLED to determine drug clearance during SLED.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>volume of distribution</measure>
    <time_frame>During the first run of SLED after study inclusion</time_frame>
    <description>Serial serum samples will be obtained after drug administration and during SLED to determine drug volume of distribition during SLED.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Critical Illness</condition>
  <condition>Kidney Injury</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
    <description>Serial serum sampling of patients receiving piperacillin/tazobactam and SLED simultaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meropenem</arm_group_label>
    <description>Serial serum sampling of patients receiving meropenem and SLED simultaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vancomycin</arm_group_label>
    <description>Serial serum sampling of patients receiving vancomycin and SLED simultaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>serial serum sampling for quantification of drug concentration</intervention_name>
    <arm_group_label>meropenem</arm_group_label>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
    <arm_group_label>vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        critically ill adults admitted to an ICU&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Critically ill adults [age ≥ 18] admitted to one of two of the medical/surgical&#xD;
             intensive care units (ICUs) of The Ottawa Hospital, who require SLED and are or will&#xD;
             receive meropenem, piperacillin-tazobactam or vancomycin therapy at any dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients for whom participation via the informed consent process is denied.&#xD;
&#xD;
          -  Critically ill patients with a hypermetabolic state due to &gt;25% coverage of body&#xD;
             surface area burn, cystic fibrosis, spinal cord injury, bariatric patients (defined as&#xD;
             &gt;150kg total body weight)&#xD;
&#xD;
          -  Patient is pregnant as per a positive serum or urine βHCG qualitative assay&#xD;
&#xD;
          -  Patient does not have a closed-system arterial or central venous catheter (to minimize&#xD;
             blood wastage)&#xD;
&#xD;
          -  Patients receiving concomitant drugs known to interact with the metabolism or&#xD;
             clearance of the antimicrobial of interest according to Micromedex 2.0 (Truven Health&#xD;
             Analytics Inc 2013)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 9, 2014</study_first_submitted>
  <study_first_submitted_qc>September 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2014</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

